Higher lipocalin 2 expression may represent an independent favorable prognostic factor in cytogenetically normal acute myeloid leukemia

Leukemia and Lymphoma

Volumn 54, Issue 8, 2013, Pages 1614-1625

  Yang, Wen Chi ^a,b   Lin, Pai Mei ^c   Yang, Ming Yu ^d   Liu, Yi Chang ^a,e   Chang, Chao Sung ^a,b   Chou, Wen Chien ^f   Hsu, Jui Feng ^a   Huang, Chiung Tang ^a   Cho, Shih Feng ^a   Yu, Wen Hui ^a   Lin, Sheng Fung ^a,e  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acute myeloid leukemia; Cytogenetically normal; Lipocalin 2 (LCN2); Prognosis

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; CYTARABINE; DAUNORUBICIN; MESSENGER RNA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; INDUCTION CHEMOTHERAPY; LEUKEMIA CELL LINE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; WILD TYPE;

ACUTE-PHASE PROTEINS; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CCAAT-ENHANCER-BINDING PROTEINS; CELL LINE; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; LIPOCALINS; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; YOUNG ADULT;

EID: 84880262102     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.749402     Document Type: Article

References (45)

1. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100 : 4325-4336
2. Gaidzik V I, Bullinger L, Schlenk R F, et a l. RUNX1 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol 2011 ; 29 : 1364-1372
3. Langer C, Marcucci G, Holland KB, et al. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-Associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study. J Clin Oncol 2009 ; 27 : 3198-3204
4. Langer C, Radmacher MD, Ruppert AS, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years withacute myeloid leukemia: A Cancer and Leukemia Group B (CALGB) study. Blood 2008 ; 111 : 5371-5379
5. Marcucci G, Maharry K, Whitman S P, et a l. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classifi cation of cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol 2007 ; 25 : 3337-3343
6. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2010 ; 28 : 2348-2355
7. Metzeler KH, Maharry K, Radmacher M D, et a l. TET2 mutations improve the new European LeukemiaNet risk classifi cation of acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2011 ; 29 : 1373-1381
8. Neubauer A, Maharry K, Mrozek K, et al. Patients withacute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: A Cancer and Leukemia Group B study. J Clin Oncol 2008 ; 26 : 4603-4609
9. Paschka P, Marcucci G, Ruppert A S, et a l. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study. J Clin Oncol 2008 ; 26 : 4595-4602
10. Paschka P, Schlenk R F, Gaidzik V I, et a l. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010 ; 28 : 3636-3643
11. Schwind S, Maharry K, Radmacher MD, et al. Prognostic signifi cance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2010 ; 28 : 5257-5264
12. Tang J L, Hou HA, Chen C Y, et a l. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: Prognostic implication and interaction with other gene alterations. Blood 2009 ; 114 : 5352-5361
13. Li C, Chan YR. Lipocalin 2 regulation and its complex role in inflammation and cancer. Cytokine 2011; 56: 435-441
14. Bachman M A, Miller V L, Weiser J N. Mucosal lipocalin 2 has proinfl ammatory and iron-sequestering effects in response to bacterial enterobactin. PLoS Pathogens 2009; 5 : E1000622
15. Nelson AL, Barasch JM, Bunte RM, et al. Bacterial colonization of nasal mucosa induces expression of siderocalin, an ironsequestering component of innate immunity. Cell Microbiol 2005 ; 7 : 1404-1417
16. Saiga H, Nishimura J, Kuwata H, et al. Lipocalin 2-dependent inhibition of mycobacterial growth in alveolar epithelium. JImmunol 2008 ; 181 : 8521-8527
17. Gombart A F, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 2005 ; 19 : 1067-1077
18. Godinez I, Haneda T, Raffatellu M, et al. Tcells help to amplify inflammatory responses induced by Salmonella enterica serotype Typhimurium in the intestinal mucosa. Infect Immun 2008 ; 76 : 2008-2017
19. Flo T H, Smith K D, Sato S, et a l. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004 ; 432 : 917-921
20. Berger T, Togawa A, Duncan G S, et a l. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci USA 2006 ; 103 : 1834-1839
21. Devireddy LR, Gazin C, Zhu X, et al. Acell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 2005 ; 123 : 1293-1305
22. Yang J, Moses MA. Lipocalin 2: A multifaceted modulator of human cancer. Cell Cycle 2009; 8: 2347-2352
23. Lin H, Monaco G, Sun T, et al. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia. Oncogene 2005 ; 24 : 3246-3256
24. Leng X, Lin H, Ding T, et al. Lipocalin 2 is required for BCR-ABLinduced tumorigenesis. Oncogene 2008 ; 27 : 6110-6119
25. Essafi A, Fernandez de Mattos S, Hassen YA, et al. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene 2005 ; 24 : 2317-2329
26. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003 ; 21 : 4642-4649
27. Falini B, Mecucci C, Tiacci E, et al. GIMEMA: Acute Leukemia Working Party: Cytoplasmic nucleophosmin in acute myelogenous leukemia witha normal karyotype. NEngl J Med 2005; 352: 254-266
28. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999 ; 93 : 3074-3080
29. Spiekermann K, Bagrintseva K, Schoch C, et a l. Anew and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood 2002 ; 100 : 3423-3425
30. Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-Alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001 ; 27 : 263-270
31. Quentmeier H, Reinhardt J, Zaborski M, et a l. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 2003 ; 17 : 120-124
32. Schwende H, Fitzke E, Ambs P, et al. Differences in the state of differentiation of THP-1 cells induced by phorbol ester and 1,25- dihydroxyvitamin D3. JLeukoc Biol 1996 ; 59 : 555-561
33. Chou WC, Hou HA, Chen CY, et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 2010 ; 115 : 2749-2754
34. Alonci A, Allegra A, Russo S, et al. Imatinib mesylate therapy induces reduction in neutrophil gelatinase-Associated lipocalin serum levels and increase in leptin concentrations in chronic myeloid leukemia patients in molecular remission. Acta Haematol 2012; 127: 1-6
35. Andrews NC. Molecular control of iron metabolism. Best Pract Res Clin Haematol 2005 ; 18 : 159-169
36. Mül ler I, Niethammer D, Bruchelt G. Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review). Int J Mol Med 1998 ; 1 : 491-494
37. Guo M, Song LP, Jiang Y, et al. Hypoxia-mimetic agents desferrioxamine and cobalt chloride induce leukemic cell apoptosis through different hypoxia-inducible factor-1 〈 independent mechanisms. Apoptosis 2006 ; 11 : 67-77
38. LR, Hart DO, Goetz DH, et al. Amammalian siderophore synthesized by an enzyme witha bacterial homolog involved in enterobactin production. Cell 2010; 141: 1006-1017
39. Baldus C D, Mrozek K, Marcucci G, et a l. Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is aff ected by molecular genetic alterations: A concise review. Br J Haematol 2007 ; 137 : 387-400
40. Park B G, Chi H S, Park S J, et a l. Clinical implications of non-A-Type NPM1 and FLT3 mutations in patients with normal karyotype acute myeloid leukemia. Acta Haematol 2012 ; 127 : 63-71
41. Bauer M, Eickhoff JC, Gould MN, et al. Neutrophil gelatinaseassociated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 2008 ; 108 : 389-397
42. Faca VM, Song KS, Wang H, et al. Amouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 2008; 5: E123
43. Nairz M, Theurl I, Ludwiczek S, et al. The co-ordinated regulation of iron homeostasis in murine macrophages limits the availability of iron for intracellular Salmonella typhimurium. Cell Microbiol 2007 ; 9 : 2126-2140
44. Lin HH, Li WW, Lee YC, et al. Apoptosis induced by uterine 24p3 protein in endometrial carcinoma cell line. Toxicology 2007 ; 234 : 203-215
45. Miharada K, Hiroyama T, Sudo K, et al. Lipocalin 2 functions as a negative regulator of red blood cell production in an autocrine fashion. FASEB J 2005 ; 19 : 1881-1883